摘要
目的 探讨重组人脑利钠肽(rhBNP)联合左西孟旦治疗难治性心衰的临床效果。方法 选取我院2020年1月至2021年6月收治的100例难治性心衰患者为研究对象,随机将其分为对照组和研究组,每组50例。对照组采取左西孟旦治疗,研究组在对照组基础上给予rhBNP治疗。比较两组的治疗效果。结果 研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的心输出量(CO)、每搏输出量(SV)、左心室射血分数(LVEF)、心脏指数(CI)均高于对照组(P<0.05)。治疗后,研究组的一氧化氮(NO)水平高于对照组,内皮素-1(ET-1)水平低于对照组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。治疗后,研究组的同型半胱氨酸(Hcy)、高敏C反应蛋白(hs-CRP)、N末端B型利钠肽原(NT-proBNP)水平低于对照组(P<0.05)。结论rhBNP联合左西孟旦治疗难治性心衰的效果显著,可改善患者心功能、血管内皮功能,且安全性较高。
Objective To investigate the clinical effect of recombinant human brain natriuretic peptide(rhBNP)combined with levosimendan in the treatment of refractory heart failure.Methods A total of 100 patients with refractory heart failure admitted in our hospital from January 2020 to June 2021 were selected as the research objects and randomly divided into control group and study group,with 50 cases in each group.The control group was treated with levosimendan,and the study group was treated with rhBNP based on the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the cardiac output(CO),stroke volume(SV),left ventricular ejection fraction(LVEF)and cardiac index(CI)of the study group were higher than those of the control group(P<0.05).After treatment,the level of nitric oxide(NO)in the study group was higher than that in the control group,and the level of endothelin-1(ET-1)was lower than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of homocysteine(Hcy),high-sensitivity C-reactive protein(hs-CRP)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)in the study group were lower than those in the control group(P<0.05).Conclusion The rhBNP combined with levosimendan has a significant effect in the treatment of refractory heart failure,which can improve the cardiac function and vascular endothelial function of patients,with high safety.
作者
张竹瑄
许露
ZHANG Zhuxuan;XU Lu(Xi'an Aerospace General Hospital,Xi'an 710100,China)
出处
《临床医学研究与实践》
2023年第27期41-44,共4页
Clinical Research and Practice
关键词
难治性心衰
重组人脑利钠肽
左西孟旦
心功能
refractory heart failure
recombinant human brain natriuretic peptide
levosimendan
cardiac function
